ALXO - ALX ONCOLOGY HOLDINGS INC
1.64
0.050 3.049%
Share volume: 767,234
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations:
-0.12%
PREVIOUS CLOSE
CHG
CHG%
$1.59
0.05
0.03%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-09-2024 | 08-12-2024 | 11-07-2024 | 03-06-2025 | 05-08-2025 | 11-07-2025 | 03-09-2026 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 37.762 M | 41.525 M | 32.567 M | 30.613 M | 31.820 M | 22.532 M | 23.021 M | |
| Selling general and admin | 6.045 M | 6.872 M | 6.096 M | 7.081 M | 7.932 M | 5.091 M | 5.376 M | |
| Research and development | 31.717 M | 34.653 M | 26.471 M | 23.532 M | 23.888 M | 17.441 M | 17.645 M | |
| Total expenses | 37.762 M | 41.525 M | 32.567 M | 30.613 M | 31.820 M | 22.532 M | 23.021 M | |
| 9.97% | -21.57% | -6.00% | 3.94% | -29.19% | 2.17% | |||
| Operating income | -37.762 M | -41.525 M | -32.567 M | -30.613 M | -31.820 M | -22.532 M | -23.021 M | |
| Ebit | -37.776 M | -41.533 M | -32.564 M | -30.614 M | -31.831 M | -22.538 M | -23.038 M | |
| Pretax income | -35.581 M | -39.399 M | -30.707 M | -29.163 M | -30.754 M | -22.144 M | -22.848 M | |
| 10.73% | -22.06% | -5.03% | 5.46% | -28.00% | 3.18% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -35.581 M | -39.399 M | -30.707 M | -29.163 M | -30.754 M | -22.144 M | -22.848 M | |
| -10.73% | 22.06% | 5.03% | -5.46% | 28.00% | -3.18% |